Scholarlink

Introduction <p>The incidence of colorectal cancer (CRC) is increasing with colorectal adenomas recognized as key precancerous lesions. Emerging evidence suggests that Imidazole propionate (ImP), a metabolite of gut microbiota, is elevated in patients, indicating a potential role in tumorigenesis of CRC.</p> Objectives <p>This study aimed to validate a novel method for detecting serum ImP using 3-piperazin-1-yl-propionic acid as an internal standard (IS), and to compare ImP levels between patients with colorectal adenomas and colorectal cancer.</p> Methods <p>Serum ImP were measured using Ultra-Performance Liquid Chromatography&#xa0;Tandem Mass Spectrometry (UPLC-MS/MS) with 3-piperazin-1-yl-propionic acid as the IS. Four distinct patient groups were analyzed.</p> Results <p>The use of 3-piperazin-1-yl-propionic acid as an IS was successfully validated for the quantification of ImP. Serum ImP differed significantly among the groups, showing a stepwise increase from healthy controls to patients with colorectal adenomas and CRC. Notably, ImP concentrations were significantly higher in CRC patients than in other groups.</p> Conclusion <p>This study demonstrates the successful application of 3-piperazin-1-yl-propionic acid as an IS provides a viable method for measuring serum ImP concentrations. The results suggest a potential link between ImP and colorectal cancer development.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Comparative serum imidazole propionate profiling in colorectal adenoma and cancer by UPLC-MS/MS

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年6月3日

查看全文
  • Jie Lv,
  • Qianqian Chen,
  • Lu Yang,
  • Jing Guan,
  • Sheng Wang,
  • Gen Gui,
  • Zhaoyun Yang,
  • Xu Wang,
  • Bin Sun

摘要

Introduction

The incidence of colorectal cancer (CRC) is increasing with colorectal adenomas recognized as key precancerous lesions. Emerging evidence suggests that Imidazole propionate (ImP), a metabolite of gut microbiota, is elevated in patients, indicating a potential role in tumorigenesis of CRC.

Objectives

This study aimed to validate a novel method for detecting serum ImP using 3-piperazin-1-yl-propionic acid as an internal standard (IS), and to compare ImP levels between patients with colorectal adenomas and colorectal cancer.

Methods

Serum ImP were measured using Ultra-Performance Liquid Chromatography Tandem Mass Spectrometry (UPLC-MS/MS) with 3-piperazin-1-yl-propionic acid as the IS. Four distinct patient groups were analyzed.

Results

The use of 3-piperazin-1-yl-propionic acid as an IS was successfully validated for the quantification of ImP. Serum ImP differed significantly among the groups, showing a stepwise increase from healthy controls to patients with colorectal adenomas and CRC. Notably, ImP concentrations were significantly higher in CRC patients than in other groups.

Conclusion

This study demonstrates the successful application of 3-piperazin-1-yl-propionic acid as an IS provides a viable method for measuring serum ImP concentrations. The results suggest a potential link between ImP and colorectal cancer development.